John Fesko Sells 782 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 782 shares of Natera stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18. Following the completion of the transaction, the insider owned 185,000 shares of the company’s stock, valued at $48,190,650. This trade represents a 0.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $236,539.17.
• On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The shares were sold at an average price of $202.84, for a total value of $291,683.92.
• On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $59,992.56.

Natera Price Performance

Shares of NTRA stock traded up $1.60 during trading hours on Wednesday, hitting $253.82. 925,147 shares of the company’s stock were exchanged, compared to its average volume of 1,091,572. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The stock has a market cap of $36.35 billion, a price-to-earnings ratio of -155.72 and a beta of 1.51. The stock’s 50-day moving average is $244.16 and its 200-day moving average is $221.65.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. William Blair assumed coverage on shares of Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating for the company. Barclays lowered their price target on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Wednesday, June 24th. Canaccord Genuity Group upped their price objective on Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Piper Sandler restated an “overweight” rating and set a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. Finally, BTIG Research set a $275.00 price objective on Natera and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC increased its holdings in Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares during the period. Focus Partners Wealth raised its position in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares during the period. Sivia Capital Partners LLC bought a new position in Natera during the 2nd quarter worth approximately $298,000. Finally, WINTON GROUP Ltd bought a new position in Natera during the 2nd quarter worth approximately $558,000. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.